Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”

Detalles Bibliográficos
Autores principales: Guan, Haijing, Sheng, Yanan, Guo, Wanjie, Han, Sheng, Shi, Luwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004422/
https://www.ncbi.nlm.nih.gov/pubmed/31902064
http://dx.doi.org/10.1007/s12325-019-01202-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004422/
https://www.ncbi.nlm.nih.gov/pubmed/31902064
http://dx.doi.org/10.1007/s12325-019-01202-2

Ejemplares similares